Skip to content

Treatment of Bronchial Asthma with Unani Medicine Majoon-e-Rahul Momineen.

Clinical Validation of Unani Pharmacopoeal formulation Majoon Rahul Momineen in Zeeq un Nafas (Bronchial Asthma)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/08/015398
Enrollment
240
Registered
2018-08-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma Health Condition 2: J459- Other and unspecified asthma Health Condition 3: J459- Other and unspecified asthma Health Condition 4: null- Zeeq un Nafas (Bronchial Asthma)

Interventions

Intervention1: Majoon-e-Rahul Momineen: Majoon Rahul Momineen Semisolid Oral 7g twice daily take with Lukewarm water for two weeks Control Intervention1: Nil: Nil

Sponsors

Central Council For Research In Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group of 19-60 2. Patients of Bronchial Asthma presenting with the following symptoms: Wheeze Shortness of breath Chest tightness and cough that vary over time and in intensity Expiratory airflow limitation as suggested by a decreased FEV1 Patients with Asthma Control Questionnaire Score

Exclusion criteria

Exclusion criteria: The patients of Zeequn Nafas (Bronchial Asthma) with following conditions will be excluded from the study: 1. Patient with Upper Respiratory Tract Infections, Chronic obstructive airway disease (COAD) including chronic bronchitis and emphysema. 2. Patient with medical conditions requiring long term treatment such as Pulmonary tuberculosis, Renal insufficiency Diabetes Mellitus, Hypertension etc 3. Patients with cognitive impairments 4. History of addiction (smoking, alcohol, drugs) 5. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Improvement in the sign and symptoms of Zeeq un Nafas (Bronchial Asthma)Timepoint: Two Weeks

Secondary

MeasureTime frame
Hematological and biochemical assessments for safetyTimepoint: 2 weeks

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026